AMERISAFE Says the Quiet Part: Workers' Comp Got 'Irrational'

A 29% ninety-day collapse, an audit premium that flipped negative, and the first admissions of predatory pricing from competitors — this is a different call than the last four.

AMSF · Earnings Call · 2026-10-29

The word they stopped avoiding

For a year, AMERISAFE's management had been inching toward a word it did not want to use. On the Q3 2025 call, Janelle Frost described the competitive field as static: “there hasn't been a lot of movement in terms of competitors either increasing or decreasing their appetite.” — G. Frost, CEO · 2025-10-30 By the July 2026 call, Vince Gagliano allowed that the company had seen “a little more aggression from some of our regular competitors, particularly with package carriers.” — Vincent Gagliano, Chief Risk Officer · 2026-07-22 Careful, hedged, incremental. Then on this call the hedge disappeared entirely.

It is the same players. I think we've reached a point where we're comfortable saying we're seeing some irrational behavior.
Vincent Gagliano, Chief Risk Officer · 2026-10-29

Frost's follow-up was even more specific, and it is the single most informative disclosure on the call: the mispricing isn't only in the rate. “It wasn't just pricing. We saw what I would call irrational commission structures.” — Janelle Frost, Chief Executive Officer · 2026-10-29 In states where accounts are won on dividends, they saw that lever pulled harder too. That is a competitive reading that goes past "soft market" and into something closer to a shakeout — carriers buying premium at almost any cost, including paying it out the back door through commissions. The tell is in the company's own keyword set. cancellation premium surfaced at the very top of AMERISAFE's thematic list this quarter, and Gagliano confirmed why: cancellation premium was "robust" — normal in isolation, but stacked on thin audit activity it produced the ugly optics. The company is working harder to keep what it has. Frost said as much: “Some days, Mark, I feel like we're fighting for every single account.” — Vincent Gagliano, Chief Risk Officer · 2026-10-29

The denominator problem

Gross written premium fell 4.5% to $76.7 million. Audit and related premium adjustments subtracted $1.6 million this quarter versus adding $2.5 million a year ago — a swing large enough to make unfavorable audit premium a top-three theme. Gagliano's explanation was mechanically fair (a couple of unusually large negative audits on a small base, plus a low seasonal quarter), but the underlying wage data is the more interesting signal: wage growth of roughly 4.1% in the quarter versus 6.7% a year earlier. That matters because the claim side is no longer cooperating with the premium side. Frost did not hide from it: “absolute reported claim counts are up. I would love to say, oh, it's really all premium related, but that is not true.” — Janelle Frost, Chief Executive Officer · 2026-10-29 She quickly attributed part of it to a 4% larger in-force policy base, but the admission stands — claims reported are outgrowing premium, and the loss ratio is pinned at 72% with 18 claims over $1 million through nine months against 17 at this point last year (the full year 2025 finished at 25). The rate filing picture offers no escape hatch. Approved loss costs for 2027 are still coming in at 5–6% declines, with North Carolina the mildest at -10.8%. As Frost put it, the industry expected the pace of decline to slow; instead it "stabilized." When your pricing base shrinks 5-6% a year and your claim counts grow, margin compression is arithmetic, not opinion.

The theme the market stopped pricing

Here is the quiet irony. Medical inflation has been a fixture of AMERISAFE calls for well over a year — it was a top-ranked theme in late 2025 and has since drifted down the momentum tables as the market tired of hearing it. But the pressure has not gone away; it has moved. Frost pinpointed it: “Hospitalization and hospital costs are probably where we're seeing the greatest pressure.” — Janelle Frost, Chief Executive Officer · 2026-10-29 Home health, prosthetics, and durable medical equipment remain the standing drumbeat. A theme losing keyword momentum while it is still doing real damage to the loss ratio is exactly the kind of gap between narrative and economics worth flagging.

The tape has already voted

The stock is down 28.9% over the last 90 trading days and 34.9% from its July peak of $35.45 — a single unbroken decline. That de-rating is visible in the multiples: price to net income sits near 13.4x, versus a low-20s handle as recently as late 2022, and price to revenue has compressed to roughly 1.9x from over 3.3x at the 2021 peak. The balance sheet explains part of the fear. Book value per share fell 4.8% year to date, and statutory surplus slipped to $208.4 million from $217.8 million at year-end. The investment portfolio's effective net cash position has deteriorated to about -$243 million, and leverage — liabilities at 77.8% of assets — is at the top of its range. On a 4.7-year duration book with 41% held-to-maturity carrying a $23.8 million unrealized loss, there is limited firepower to absorb another bad accident year. The operating story is genuinely two-sided: net premiums earned still grew 3%, and the tax-equivalent book yield ticked up to 4.0% on 146 basis points of roll-off pickup. But the expense ratio rose to 32.5% from 31.1%, driven by insurance assessments (Delaware the largest) on a smaller earned-premium denominator.

What would make this a bottom

Frost's answer on whether the voluntary growth slowdown is the new normal was emphatic: “No, I do not expect that to be a new normal.” — Janelle Frost, Chief Executive Officer · 2026-10-29 She reiterated the mid-single-digit growth target set at the start of the year — the same target she has repeated since April: “we're shooting for that mid-single-digit range, and we've been hitting that.” — G. Frost, CEO · 2026-04-22 The tension is that her own operators have now escalated from "intense" to "irrational," the audit tailwind has reversed, and claim counts are outpacing premium. Across the specialty insurance reporters this week, the shared vocabulary is premium growth and disciplined underwriting — the sector is loudly claiming the latter while quietly competing away the former. AMERISAFE, a $428 million small cap with a 40-year history in high-hazard classes, is making the opposite bet: walk away from the account rather than chase it. That is a defensible strategy that the market is currently pricing as a permanent loss of share.